Challenge the route, not just the date
An ambitious submission goal can prompt useful redesign when regulatory, clinical, CMC, and executive teams examine the critical path together. Distinguish requirements from work that adds effort without advancing the intended filing.
Make risk-informed tradeoffs
In one source example, commissioning 150 grams of an eventual 400-gram drug-substance need enabled studies to begin sooner, with a second batch planned later. Another review found more than 70 unnecessary tables, listings, and figures. Such choices require explicit cost, quality, and regulatory judgment. Shared scope, timely escalation, and clear ownership let teams pursue speed without treating compliance or scientific integrity as negotiable.